

## Influence of Variations in *CCL3L1* and *CCR5* on Tuberculosis in a Northwestern Colombian Population

Manju Mamtani,<sup>1,a</sup> Srinivas Mummidu,<sup>1,a</sup> Veron Ramsuran,<sup>3,4</sup> Minh-Hieu Pham,<sup>1</sup> Robert Maldonado,<sup>1</sup> Kazi Begum,<sup>1</sup> Maria Soledad Valera,<sup>1</sup> Racquel Sanchez,<sup>1</sup> John Castiblanco,<sup>1</sup> Hemant Kulkarni,<sup>1</sup> Thumbi Ndung'u,<sup>3,4</sup> Weijing He,<sup>1</sup> Juan Manuel Anaya,<sup>5,6</sup> and Sunil K. Ahuja<sup>1,2</sup>

<sup>1</sup>The Veterans Administration Center for AIDS and HIV-1 infection and Center for Personalized Medicine, South Texas Veterans Health Care System and Department of Medicine; <sup>2</sup>Departments of Microbiology and Immunology and Biochemistry, University of Texas Health Science Center, San Antonio; <sup>3</sup>Centre for the AIDS Program of Research in South Africa (CAPRISA); <sup>4</sup>HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; <sup>5</sup>Cellular Biology and Immunogenetics Unit, Corporacion para Investigaciones Biologicas, Medellin; and <sup>6</sup>School of Medicine, Universidad del Rosario, Bogota, Colombia

**We investigated the association of polymorphisms in *CCR5*, the major human immunodeficiency virus (HIV)–1 coreceptor, and copy number of its potent ligand *CCL3L1* with tuberculosis in 298 individuals from Colombia. The *CCR5*-HHD haplotype, a known genetic determinant of increased susceptibility to HIV/AIDS, and a high copy number of *CCL3L1*, a known genetic determinant of enhanced *CCL3/CCL3L1* chemokine expression, each associated with presence of tuberculosis. Furthermore, *CCR5*-HHD was associated with higher *CCR5* gene and surface expression. These results substantiate the strong link between the pro-inflammatory effects of *CCR5* and its ligands with active tuberculosis and suggest that chemokine-chemokine receptor genetic determinants may influence tuberculosis in addition to HIV/AIDS.**

Tuberculosis (TB) is still widespread, and according to the World Health Organization, 2 billion people are infected with the causative bacillus *Mycobacterium tuberculosis* [1]. Although ~10% of infected persons develop active TB, the precise basis by which the majority of infected persons never experience progression to active TB remains unknown [1]. In addition to the environment and bacterium, host genetic differences that influence the inflammatory response are thought to contribute significantly to the final outcome of infection [1].

Genes encoding chemokines and their cognate receptors play a key role in the inflammatory response during TB. Prior studies have shown that (1) CC chemokine receptor 5 (*CCR5*), the major human immunodeficiency virus (HIV)–1 coreceptor, is highly expressed on T helper (Th) 1 cells (discussed in [2]); (2) Th1 responses play a critical role in immunity against TB [3]; (3) compared with healthy individuals, the levels of *CCR5* are elevated in Th cells in patients with pulmonary TB [3, 4]; (4) *CCR5* expression is increased in humans and rhesus monkeys with active TB [5, 6]; (5) the ligands of *CCR5*, such as *CCL3* and *CCL5*, are also increased during TB [3, 4, 6, 7]; and (6) cell-mediated immunity (CMI) is a central determinant of TB resistance [3], and both *CCR5* and *CCL3L1*, the most potent ligand of *CCR5* [8], influence CMI (discussed in [9]). However, the association of variations in the chemokine-chemokine receptor pair *CCL3L1* and *CCR5* with TB in HIV-negative subjects is unknown. Together, these observations prompted us to test the hypothesis that variations in *CCR5* and *CCL3L1* gene copy number are associated with TB susceptibility. We tested this hypothesis in individuals with and without TB who were recruited from a well-defined northwestern Colombian population.

### METHODS

#### Study Subjects

We evaluated 114 patients with TB and 184 healthy control subjects from the Paisa community in northwestern Colombia (South America), where TB has moderately-high endemicity. Additional characteristics of the study participants have been described, (see [10] and Supplementary Methods). Historical and genetic evidence suggest that this community is genetically isolated, with a documented low degree of admixture and a calculated ancestral ethnic composition of 85% white, 15% Amerindian, and a non-significant African contribution (see Supplementary Methods).

#### Genotyping

The methods for genotyping the *CCR5* polymorphisms that allow for generation of the 9 major *CCR5* haplotypes are as

Received 18 February 2010; accepted 14 January 2011.

Potential conflicts of interest: none reported.

<sup>a</sup>M.M. and S.M. contributed equally to this article.

Correspondence: Sunil K. Ahuja, MD, VA Center for Personalized Medicine and University of Texas Health Science Center, San Antonio, TX, 78229 (ahuja@uthscsa.edu).

**The Journal of Infectious Diseases** 2011;203:1590–4

© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

0022-1899 (print)/1537-6613 (online)/2011/20311-0013\$14.00

DOI: 10.1093/infdis/jir145

described elsewhere [8, 11, 12]. *CCL3L1* gene copy number was determined as described elsewhere [8]. We genotyped a validated set of 96 ancestry informative markers (AIMs) using TaqMan genotyping assays (see Supplementary Methods).

### Reporter Assays and *CCR5* Expression

We introduced promoter sequences specific to HHA, HHB, and HHD *CCR5* haplotypes into a firefly luciferase reporter vector and then evaluated the transcriptional strength of these haplotype-specific reporter constructs in in vitro transcription assays using methods described elsewhere [12] and in the Supplementary Methods section. Transcriptional activity was assessed in a Jurkat T-cell line and in anti-CD3/CD28 activated peripheral blood mononuclear cells (PBMCs) from healthy persons (see Supplementary Methods). *CCR5* levels on CD4<sup>+</sup> T cells were assessed by fluorescence activated cell sorting (see Supplementary Methods).

### Statistical Analysis

The association of *CCR5* haplotypes or *CCL3L1* gene copy number with the risk of TB was evaluated using multiple logistic regression analyses. On the basis of the mean *CCL3L1* copy number found in the control group (which was 2), we stratified the study subjects into 3 groups: those with <2, 2, or >2 *CCL3L1* copies. We examined the potential contribution of population admixture to genotype-phenotype associations by using 96 AIMs with the EIGENSTRAT method and STRUCTURE software (see Supplementary Methods).

## RESULTS

On the basis of linkage disequilibrium patterns, the major polymorphisms in *CCR2-CCR5* were categorized into 9 *CCR5* haplotypes, as described elsewhere ([12]; Figure 1A). We found that all of the polymorphisms typed were in Hardy-Weinberg equilibrium in control subjects. The *CCR5-HHC* haplotype was the most common haplotype in both case patients and control subjects, followed by HHE and HHF\*2 (Figure 1B). In control subjects, 2 copies of *CCL3L1* was the median gene copy number, whereas in case patients 2 and 3 *CCL3L1* copies were the most frequent values (Figure 1C).

The proportion of men was higher among case patients ( $n = 50$  patients [56.82%]) than among control subjects ( $n = 38$  patients [43.18%]). The mean patient age ( $\pm$  standard deviation) was  $39.83 \pm 16.17$  years, whereas the mean age ( $\pm$  standard deviation) of the control subjects was  $46.41 \pm 16.04$  years. Younger age (odds ratio [OR], = 0.98; 95% confidence interval [CI], = 0.97–0.99;  $P = .003$ ) and male sex (OR, = 3.08; 95% CI, = 1.82–5.22;  $P < .001$ ) was significantly associated with presence of TB. We therefore included these 2 variables along with the *CCR5* haplotypes and a copy number of *CCL3L1* that was less than or greater than 2 copies in a single multiple logistic regression model, to determine whether variations in *CCR5* and


*CCL3L1* were independently associated with TB. In the full model, *CCR5-HHD* (OR, = 4.32; 95% CI, = 1.27–14.7;  $P = .019$ ) and possession of >2 *CCL3L1* copies (OR, = 1.84; 95% CI, = 1.02–3.31;  $P = .043$ ) were significantly and independently associated with the presence of TB (Table 1, full model).

In the final step-wise regression model, we found that, independent of age and sex, *CCR5-HHD* haplotype (OR, = 3.95; 95% CI, = 1.28–12.18;  $P = .017$ ) and possession of >2 *CCL3L1* copies (OR, = 1.75; 95% CI, = 1.04–2.92;  $P = .034$ ) were significantly associated with the presence of TB (Table 1, final model). Concordant results were obtained when we analyzed only those control subjects ( $n = 85$ ) who had a tuberculin reaction of  $\geq 10$  mm (data not shown).

Because the *CCR5-HHD* haplotype is commonly found in persons of African ancestry but is also present in individuals of European and Hispanic ancestry [11], we examined whether the associations observed for this haplotype were because of potential population admixture. However, we found that genetic stratification was an unlikely explanation for the observed association of *CCR5-HHD* with risk of TB (Supplementary Figure 1). Collectively, these observations suggested that both the *CCR5-HHD* haplotype and a high *CCL3L1* gene copy number were strongly associated with the presence of TB in the study population.

A high *CCL3L1* gene copy number is a genetic determinant of increased *CCL3/CCL3L1* expression [8], and this may provide a possible functional basis by which this chemokine genotype affects TB pathogenesis. It is unknown whether the single nucleotide polymorphism (SNP) at –2132T that distinguishes the *CCR5-HHD* haplotype from all other haplotypes (Figure 1A) has an impact on gene expression. To evaluate this, we considered the following framework. *CCR5-HHA* haplotype is the ancestral haplotype, and *CCR5* haplotypes can be broadly dichotomized into those containing –2459G/–2135T (HH-A, -B, -C, and -D) versus –2459A/–2135C (HH-E, -F, and -G) (Figure 1A) [12]. We demonstrated previously that, compared with the promoter sequences of –2459A/–2135C-containing haplotypes (HHE, HHF, or HHG), the HHA promoter sequence exhibited the least transcriptional activity [12]. Because –2459G/–2135T is common to HHA, HHB, HHC, and HHD haplotypes (Figure 1A), one possibility was that the promoters of these 4 haplotypes have similar transcriptional strengths. An alternative possibility was that the combinatorial content of promoter SNPs that differentiate HHB, HHC, and HHD from the ancestral HHA (Figure 1A) uniquely affects gene expression.

We found previously that, in the K562 cell line, HHA- and HHC-specific promoter sequences had similarly low transcriptional activity [12]. Here, we found that, in the Jurkat T-cell line, *CCR5-HHB* and *CCR5-HHD* promoter sequences had higher transcriptional activity than did HHA (Figure 1D). We conducted similar transcriptional analyses in primary PBMCs obtained from healthy persons. These analyses revealed that although there was some donor-to-donor variability, promoter



**Figure 1.** Distribution of *CCR5/CCL3L1* genotypes and influence of *CCR5* promoter polymorphisms on gene and surface expression. **A**, Schematic represents the evolutionary relationship among *CCR5* human haplogroups (HH) that contain the major *CCR5* haplotypes designated as HH-A, -B, -C, -D, -E, F\*1, F\*2, G\*1, and G\*2 [12]. Haplotype classification is based on the linkage disequilibrium of the indicated 9 polymorphisms in *CCR2* (V64I), *CCR5* promoter 1 (Pr1), and the *CCR5* open reading frame (ORF;  $\Delta$ 32) [12]. *CCR5*-HHA is the ancestral haplotype based on the evolutionary conservation at the indicated nucleotide positions with the chimpanzee *CCR5* [12]. Nucleotide numbering is according to Mummidi et al [12]. The signature single-nucleotide polymorphisms (SNPs) that distinguish *CCR5* haplotypes from the ancestral haplotype are in boldface font. The haplotypes studied in this report are highlighted in colored boxes and are color-matched. **B** and **C**, Distribution of *CCR5* haplotypes (**B**) and *CCL3L1* gene copy number (**C**) in case patients ( $n = 114$ ) and control subjects ( $n = 184$ ). **D**, Box-whisker plot showing haplotype-specific differences in *CCR5* gene transcriptional activity in Jurkat T cells. Cells were cotransfected with HHA-, HHB-, and HHD-specific firefly luciferase reporter constructs and *Renilla* luciferase construct, and dual luciferase assays were performed. Data shown are from 4 independent experiments, and the transcriptional activity was log-transformed after normalization to HHA (see Supplementary Methods). Significance values shown at the top for the indicated comparisons were obtained using the Mann-Whitney *U* test. **E**, Haplotype-specific differences in *CCR5* transcriptional activity in peripheral blood mononuclear cells (PBMCs). Haplotype-specific HHA (green), HHB (blue), and HHD (red) promoter constructs were nucleofected into PBMCs stimulated with anti-CD3/CD28 antibodies and transcriptional activity was assessed. All data were normalized to the transcriptional activity of the HHA-containing reporter vector. **F**, *CCR5* surface expression on CD4<sup>+</sup>HLA-DR<sup>+</sup> cells in a cohort of 90 human immunodeficiency virus-uninfected sex workers from South Africa. *CCR5* expression was log-transformed. The height of the bar indicates the mean *CCR5* surface expression in subjects who possess (+) or lack (-) the *CCR5*-HHD haplotype, and the error bars indicate the standard error of the mean. The *P* values were calculated using the Student *t*-test.

**Table 1. Association of *CCR5* Haplotypes and *CCL3L1* Gene Copy Number With Tuberculosis**

<i>CCR5/CCL3L1</i>	Full model, OR (95% CI)					
	Unadjusted			Adjusted <sup>a</sup>		
	OR	(95% CI)	<i>P</i>	OR	95% CI	<i>P</i>
<i>CCR5</i> HHA	1.01	(0.42–2.40)	.985	1.28	(0.52–3.15)	.591
<i>CCR5</i> HHC	1.17	(0.57–2.41)	.666	1.26	(0.59–2.70)	.555
<b><i>CCR5</i> HHD</b>	<b>4.13</b>	<b>(1.27 - 13.5)</b>	<b>.019</b>	<b>4.32</b>	<b>(1.27 - 14.7)</b>	<b>.019</b>
<i>CCR5</i> HHE	0.70	(0.36–1.37)	.299	0.78	(0.38–1.59)	.493
<i>CCR5</i> HHF*1	1.24	(0.36–4.22)	.732	1.13	(0.30–4.20)	.860
<i>CCR5</i> HHF*2	0.90	(0.44–1.86)	.778	1.04	(0.48–2.25)	.919
<i>CCR5</i> HHG*1	1.21	(0.55–2.67)	.632	1.44	(0.62–3.33)	.399
<i>CCR5</i> HHG*2	0.81	(0.13–4.89)	.815	1.04	(0.14–7.63)	.965
<i>CCL3L1</i> <2 copies	1.04	(0.46–2.32)	.931	1.18	(0.51–2.76)	.695
<b><i>CCL3L1</i> &gt;2 copies</b>	<b>1.94</b>	<b>(1.11 - 3.38)</b>	<b>.019</b>	<b>1.84</b>	<b>(1.02 - 3.31)</b>	<b>.043</b>
Final Model <sup>b</sup>						
<i>CCR5/CCL3L1</i>						
<b><i>CCR5</i> HHD</b>	<b>4.15</b>	<b>(1.42 - 12.13)</b>	<b>.009</b>	<b>3.95</b>	<b>(1.28 - 12.18)</b>	<b>.017</b>
<b><i>CCL3L1</i> &gt;2 copies</b>	<b>1.95</b>	<b>(1.19 - 3.17)</b>	<b>.007</b>	<b>1.75</b>	<b>(1.04 - 2.92)</b>	<b>.034</b>

**NOTE.** Boldface type indicates statistical significance. CI, confidence interval; OR, odds ratio.

<sup>a</sup> Adjusted for age and sex.

<sup>b</sup> The results for the final model are from step-wise multiple logistic regression analysis with a retention criterion of .1.

sequences of HHB—and especially those of HHD—had higher transcriptional activity than did those of HHA in anti-CD3/CD28 activated PBMCs (Figure 1E). To assess whether the higher gene expression associated with *CCR5*-HHD translates to increased protein expression, we evaluated a cohort of 90 black, HIV-negative female sex workers from South Africa who were part of the CAPRISA 002 acute infection study (see Supplementary Methods). In these women, compared with women who lacked HHD, those possessing *CCR5*-HHD had higher *CCR5* expression on CD4<sup>+</sup>HLA-DR<sup>+</sup> T cells (Figure 1F). Of note, although *CCR5*-HHB is rare, like *CCR5*-HHD, it is also more prevalent among persons of African ancestry [11] and consistent with the results of our transcriptional studies, the 2 women who had HHB-containing genotypes also had high *CCR5* surface expression (data not shown).

In previous studies, we demonstrated that the G→T transversion at position –2554 (common to HHB, HHC, and HHD) associates with differences in binding of the NF-κB family of transcription factors [12]. Here, we found that nuclear factors from Jurkat T cells bound differentially to –2132T and –2132C alleles (Supplementary Figure 2). Although bioinformatic analyses suggested the binding of FOXO family transcription factors to the *cis*-regions in the close vicinity of HHD-specific SNP at –2132, competition electrophoretic mobility shift assays with oligonucleotides containing FOXO consensus sequences were not conclusive (Supplementary Figure 2).

## DISCUSSION

We found that the *CCR5*-HHD haplotype and a copy number of *CCL3L1* that is greater than the average found in a northwestern Colombian population was associated with a greater likelihood of active TB. These results support our hypothesis that *CCR5* and its potent ligand *CCL3L1* may contribute to TB pathogenesis.

The primary host immune response, which includes chemokine-dependent leukocyte recruitment and consequent granuloma formation, favors the host by providing local control of mycobacterial spread. The precise factors that tilt the balance from contained infection to active TB are unknown. However, there is increasing recognition that TB is an immunopathological disease, in which active TB develops due to uncontrolled host inflammatory responses to the pathogen (discussed in [7]). Thus, the concept was advanced that among immunocompetent hosts, the outcome of TB is a result of quantitatively and genetically controlled differences in the magnitude of the inflammatory responses, rather than a direct consequence of mycobacterial colonization [7]. This is in accord with burgeoning data suggesting a critical role of the proinflammatory effects of chemokines and their receptors in TB pathogenesis, including *CCR5* and its ligands. Notably, the *CCR5* ligand–*CCR5* receptor axis plays a key role in amplifying immune responses (discussed in [2]).

The gene encoding *CCL3L1* is subject to gene copy number variation (range, 0–12), with higher copies in persons of African ancestry [8]. Because *CCL3L1* copy number is associated with increased *CCL3/CCL3L* chemokine production [8], it is conceivable that a high copy number may associate with proinflammatory state that leads to enhanced immunopathology that favors development of active TB. This possibility is underscored by the observation that increased *CCL3* levels favor TB progression [7] and that the pro-inflammatory effects of *CCL3* may contribute to tissue inflammation independently of *M. tuberculosis* load [6, 7]. Conceivably, in the context of persons concurrent HIV infection and TB, the protective HIV-suppressive effects of high *CCL3L1* chemokine expression may be offset by its pro-inflammatory effects on TB.

Our reporter gene studies indicate that the combinatorial SNP makeup of the *CCR5*-HHD haplotype is associated with enhanced *CCR5* gene expression in activated PBMCs. As a corollary, *CCR5*-HHD is also associated with higher surface expression on activated (HLA-DR<sup>+</sup>) CD4<sup>+</sup> T cells. Together, these findings provide a possible functional basis for the observed association of *CCR5*-HHD with active TB and underscore the importance of accounting for the combinatorial content of SNPs in the *CCR5* promoter haplotypes when evaluating their impact on gene/surface expression.

Interestingly, *CCR5* HHD-containing genotypes have also been associated with adverse outcomes in HIV/AIDS, a clinical setting in which higher levels of *CCR5* are a strong correlate of

increased susceptibility to HIV infections and AIDS. Of note, we and others have shown that compared with those genotypes that do not contain HHD, *CCR5* HHD-containing genotypes are associated with an increased risk of acquiring HIV infection [13, 14], having higher plasma viral loads [15], experiencing a significant increase in vaginal shedding of HIV-1-infected cells [16], and having faster rates of progression to AIDS and death [11, 16]. Thus, it is possible that *CCR5*-HHD haplotype may serve as a common genetic factor for both HIV infection and TB. Intriguingly, the *CCR5*-HHD haplotype is found more commonly in persons of African ancestry, and whether its dual influence on HIV infection and TB susceptibility contributes to the growing burden of concurrent HIV infection and TB in Africa requires further evaluation. Taken together, the results of our association studies substantiate the accumulating data suggesting a strong role for *CCR5* and its ligands in TB pathogenesis.

## Supplementary Data

Supplementary methods and figures are available at <http://jid.oxfordjournals.org/> online.

## Funding

This work was supported by the Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and the NIH (R37046326), a VA MERIT award, the Elizabeth Glaser Scientist Award, the Burroughs Wellcome Clinical Scientist Award in Translational Research, and the Doris Duke Distinguished Clinical Scientist Award to S. K. A. The work was also supported by a VA MERIT award to S. M.

## Acknowledgments

We thank Alvaro Gaitan for advice, Florian Hladik for assistance with flow cytometry analyses, Salim S. Abdool Karim and the CAPRISA 002 study, and study participants of the CAPRISA cohort. We regret that, because of space constraints we were unable to cite other excellent work.

## References

- Moller M, Hoal EG. Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. *Tuberculosis (Edinb)* **2010**; 90:71–83.
- Camargo JF, Quinones MP, Mummidi S, et al. *CCR5* expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. *J Immunol* **2009**; 182:171–82.
- Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. *Cytokine Growth Factor Rev* **2003**; 14:467–77.
- Qiu L, Huang D, Chen CY, et al. Augmented chemokine levels and chemokine receptor expression on immune cells during pulmonary tuberculosis. *Hum Immunol* **2009**; 70:110–5.
- Pokkali S, Das SD, Expression RL. of CXC and CC type of chemokines and its receptors in tuberculous and non-tuberculous effusions. *Cytokine* **2008**; 41:307–14.
- Qiu L, Huang D, Chen CY, et al. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. *J Infect Dis* **2008**; 198:1514–9.
- Lyadova IV, Tsiganov EN, Kapina MA, et al. In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of gr-1 cells in the lungs. *PLoS One* **2010**; 5:e10469.
- Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. *Science* **2005**; 307:1434–0.
- Catano G, Chykarenko ZA, Mangano A, et al. Concordance of *CCR5* genotypes that influence cell-mediated immunity and HIV disease progression rates. *J Infect Dis* **2011**; 203:263–72.
- Gomez LM, Anaya JM, Vilchez JR, et al. A polymorphism in the inducible nitric oxide synthase gene is associated with tuberculosis. *Tuberculosis (Edinb)* **2007**; 87:288–94.
- Gonzalez E, Bamshad M, Sato N, et al. Race-specific HIV-1 disease-modifying effects associated with *CCR5* haplotypes. *Proc Natl Acad Sci U S A* **1999**; 96:12004–9.
- Mummidi S, Bamshad M, Ahuja SS, et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA: potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. *J Biol Chem* **2000**; 275:18946–61.
- Kostrikis LG, Neumann AU, Thomson B, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. *J Virol* **1999**; 73:10264–71.
- Malhotra R, Hu L, Song W, et al. Association of chemokine receptor gene (*CCR2*-*CCR5*) haplotypes with acquisition and control of HIV-1 infection in Zambians. *Retrovirology* **2011**; 8:22.
- Tang J, Wilson CM, Schaen M, Myracle A, Douglas SD, Kaslow RA. *CCR2* and *CCR5* genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. *AIDS Res Hum Retroviruses* **2002**; 18:403–12.
- John GC, Bird T, Overbaugh J, et al. *CCR5* promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. *J Infect Dis* **2001**; 184:89–92.